New nasal spray could prevent migraines without drugs
NCT ID NCT07100496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a nasal spray called MIG-SPRAY for preventing migraines in 45 adults aged 18-55. The spray forms a protective film inside the nose to possibly stop migraine triggers. Participants use it three times daily for three months, and researchers track side effects and migraine frequency compared to a control group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MIG-SPRAY (a film-forming liquid nasal spray, classified as a medical device)
What this could lead to
If it works, this could offer a new, non-drug option for preventing migraines with fewer side effects.
What could go wrong
This is a small, early-phase trial focused on safety, not effectiveness. The device may not reduce migraines significantly, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Clermont-ferrand
Clermont-Ferrand, 63000, France